These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 15908240)
1. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Haase VH Semin Cell Dev Biol; 2005; 16(4-5):564-74. PubMed ID: 15908240 [TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
3. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Kapitsinou PP; Haase VH Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317 [TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Kaelin WG Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293 [TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin WG Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019 [TBL] [Abstract][Full Text] [Related]
6. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
8. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. He Z; Liu S; Guo M; Mao J; Hughson MD Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424 [TBL] [Abstract][Full Text] [Related]
9. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. Kuehn EW; Walz G; Benzing T Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Zimmer M; Doucette D; Siddiqui N; Iliopoulos O Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465 [TBL] [Abstract][Full Text] [Related]
11. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493 [TBL] [Abstract][Full Text] [Related]
12. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene]. Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350 [TBL] [Abstract][Full Text] [Related]
13. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Kaelin WG Cancer; 2009 May; 115(10 Suppl):2262-72. PubMed ID: 19402056 [TBL] [Abstract][Full Text] [Related]
14. Role of VHL gene mutation in human cancer. Kim WY; Kaelin WG J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513 [TBL] [Abstract][Full Text] [Related]
15. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486 [TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Kaelin WG Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749 [TBL] [Abstract][Full Text] [Related]
17. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212 [TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362 [TBL] [Abstract][Full Text] [Related]
19. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]. Moch H Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708 [TBL] [Abstract][Full Text] [Related]
20. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Turcotte S; Desrosiers RR; Beliveau R Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]